Immunic Goodwill and Intangible Assets 2013-2025 | IMUX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Immunic goodwill and intangible assets from 2013 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Immunic goodwill and intangible assets from 2013 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.9B
Amgen (AMGN)	$155B
Gilead Sciences (GILD)	$141.4B
Vertex Pharmaceuticals (VRTX)	$99.8B
Bristol Myers Squibb (BMY)	$96.9B
GSK (GSK)	$81.3B
CSL (CSLLY)	$67.8B
Regeneron Pharmaceuticals (REGN)	$62.2B
Alnylam Pharmaceuticals (ALNY)	$59.5B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$28.4B
BioNTech SE (BNTX)	$24.8B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.9B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.7B
Exelixis (EXEL)	$10.4B
Moderna (MRNA)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.8B
Halozyme Therapeutics (HALO)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B